Evotec Lifts FX Hedge Floor to 75% as Gates Extends Stem-Cell Funding
Published on 11/17/2026 at 14:31 | Editorial boerse-global.deEvotec has raised the minimum hedging ratio for its currency exposure from 50% to 75%, sharpening the group's defences against foreign-exchange swings. The change to its FX management sets a higher coverage threshold, a step that can aid planning visibility for investors but does nothing by itself to lift the operating business.
The hedging upgrade sits alongside a broader push to automate treasury work. A new system now displays roughly 90% of account balances automatically each day, run by a six-person team. That gives the finance function closer, more transparent oversight of available funds — a control and monitoring gain rather than a contribution to earnings.
Convertible Bond Draws Strong Demand
Evotec's convertible bond met heavy subscription, a encouraging signal for its access to that financing channel. Strong take-up for the instrument should not be read as equivalent demand for the equity, however. For shareholders, how a company funds itself and how its share price behaves are separate questions.
The treasury work has also earned Evotec a nomination for the "Treasury of the Year 2026" award, which The Treasurer will present on 26 November 2026. Evotec appears on the shortlist alongside Freudenberg, SAP and Tennet Germany. The nod recognises the finance team's efforts; it is neither a prize already won nor a verdict on the stock's appeal.
Should investors sell immediately? Or is it worth buying Evotec?
Gates Foundation Backs Fetal-Risk Research
On the science side, Evotec received a grant of $2.9 million from the Gates Foundation for a further three years. The money extends research using human stem-cell-based methods to assess, at an early stage, potential risks that drug candidates pose to fetal development. Shares slipped 1.7% in the prior session.
Evotec also decided on 9 November to buy back up to 365,000 of its own shares, with a total purchase price of up to €2,000,000 excluding transaction costs. The programme runs from 10 November to 18 December, and the repurchased stock is to be converted into ADSs and used for an employee share scheme.
Berenberg Sticks With Hold
Berenberg lifted its price target for Evotec from €3.60 to €3.75 on 5 November, keeping its "Hold" rating. Analyst Christian Ehmann called the third quarter solid.
Evotec at a turning point? This analysis reveals what investors need to know now.
For the first nine months of 2026, Evotec reported group revenue of €465.0 million and an adjusted group EBITDA of ?€44.3 million. Guidance for 2026, which the company reaffirmed, points to group revenue of €570 million to €610 million and adjusted group EBITDA of ?€105 million to ?€70 million.
Finance Gains Are Not an Earnings Turnaround
The narrowed loss marks an improvement, though not yet a profit. Investors are therefore better off treating the finance-side advances as a supporting factor rather than a substitute for a durable earnings recovery. The distinction is straightforward: Evotec is sharpening the tools it uses to raise money, track liquidity and hedge risk. Whether that translates into a more compelling case for shareholders still rests on how the operating business develops.
Ad
Evotec Stock: New Analysis - 17 November
Fresh Evotec information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
